PD-1 and PD-L1 blockade has greatly improved the prognosis of cancer patients and favorable outcomes have been observed since Food and Drug Administration (FDA) approved the first immune checkpoint inhibitor (pembrolizumab) in 2014. This evidence concerns the gene PDCD1 and cancer.